cohen
Mauna Kea Technologies announces that first Cellvizio optical biopsy probe designed for urological applications is now ce marked
- 05/12/2012 |
- 11:40 am |
- valerie
PARIS, December 5, 2012 – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, announced today that its UroFlex™ confocal miniprobe received CE mark approval for use during cystoscopy procedures. UroFlex is the first optical biopsy probe designed for urological applications and allows the company to enter the €1 billion European urology device market.[i] The new probe allows physicians to obtain optical biopsies that may facilitate the diagnosis, surveillance and treatment of patients with bladder cancer.
PHARNEXT raises an additional €8 million for its PleotherapyTM platform applied to the treatment of Charcot-Marie Tooth disease and Alzheimer’s disease
- 09/02/2012 |
- 12:12 pm |
- valerie
Paris, February 9th 2012 – Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it has raised €8 million in two tranches in October and December 2011. This fundraising follows a €2.5 million round closed in June 2011.
PHARNEXT announces a €2.5 million round of financing
- 12/09/2011 |
- 3:46 pm |
- valerie
Paris, September 8th 2011 – Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™ for severe neurological diseases, today announced that it has put together a €2.5 million round of financing (corresponding to a pre-money company valuation of €60 million).
(Français) Mauna kea : Résultats du premier semestre 2011
- 31/08/2011 |
- 9:06 am |
- valerie
(Français) Paris, le 31 août 2011. Mauna Kea Technologies (NYSE Euronext : MKEA), leader dans le domaine de l’endomicroscopie, annonce aujourd’hui ses résultats du premier semestre de l’exercice en cours, clos au 30 juin 2011.
(Français) Mauna Kea Technologies lance son introduction en bourse sur le marché réglementé de NYSE Euronext à Paris
- 23/06/2011 |
- 1:57 pm |
- valerie
(Français) Paris, le 21 juin 2011 : Mauna Kea Technologies, leader dans le domaine de l’endomicroscopie, annonce le lancement de son introduction en bourse en vue de l’admission aux négociations de ses actions sur le marché réglementé de NYSE Euronext à Paris, compartiment B ou C.
(Français) Dans le cadre de son projet d’introduction en bourse sur NYSE Euronext Paris, Mauna Kea Technologies annonce l’enregistrement de son document de base par l’Autorité des marchés financiers
- 07/06/2011 |
- 2:03 pm |
- valerie
(Français) Paris, le 7 juin 2011 – Mauna Kea Technologies, leader dans le domaine de l’endomicroscopie, annonce l’enregistrement de son document de base par l’Autorité des marchés financiers (AMF) sous le numéro I.11-035 en date du 6 juin 2011.
PHARNEXT reçoit l’autorisation pour un essai clinique de Phase II avec son premier médicament issu de sa technologie de Pléothérapie TM
- 03/12/2010 |
- 6:19 pm |
- France Biotech
The French Agency for Healthcare Product Safety (AFSSAPS) authorizes the trial in patients suffering from Charcot-Marie-Tooth disease type 1A
